Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Workman

Showing results (51-60 of 268) with videos related to

Pageof 27
Sort By:
International Journal of Radiation Oncology, Biology, Physics|August 1, 1984
Pharmacology of the mixed-function radio- and chemosensitizers CB 1954 and RSU 1069P Workman, M I Walton
International Journal of Radiation Oncology, Biology, Physics|March 1, 1982
Enhancement by electron-affinic agents of the therapeutic effects of cytotoxic agents against the KHT tumor: structure-activity relationshipsP Workman, P R Twentyman
Biomedicine / [Publiee Pour L'A.A.I.C.I.G.]|October 1, 1978
Drug latentiation in cancer chemotherapyP Workman, J A Double
Anti-Cancer Drug Design|October 2, 1998
Bioreductive drugs into the next millenniumI J Stratford, P Workman
Radiation Research|April 1, 1980
Partition coefficient as a guide to the development of radiosensitizers which are less toxic than misonidazoleJ M Brown, P Workman
Cancer Treatment Reports|February 1, 1980
Phenytoin sodium-induced alterations in the pharmacokinetics of misonidazole in the dogR A White, P Workman
Biochemical Pharmacology|October 1, 1982
Effects of the xanthine oxidase inhibitor allopurinol on the renal clearance of nitroimidazolesP Workman, R A White
Cancer Chemotherapy and Pharmacology|January 1, 1988
When can the infusion period be safely ignored in the estimation of pharmacokinetic parameters of drugs in humans?L S Freedman, P Workman
The Journal of Pharmacology and Experimental Therapeutics|May 1, 1993
Pharmacokinetics and bioreductive metabolism of the novel benzotriazine di-N-oxide hypoxic cell cytotoxin tirapazamine (WIN 59075; SR 4233; NSC 130181) in miceM I Walton, P Workman
Biochemical Pharmacology|April 15, 1992
DT-diaphorase and cancer chemotherapyR J Riley, P Workman
Pageof 27

Showing results (51-60 of 268) with videos related to

Sort By:
Pageof 27
International Journal of Radiation Oncology, Biology, Physics|August 1, 1984
Pharmacology of the mixed-function radio- and chemosensitizers CB 1954 and RSU 1069P Workman, M I Walton
International Journal of Radiation Oncology, Biology, Physics|March 1, 1982
Enhancement by electron-affinic agents of the therapeutic effects of cytotoxic agents against the KHT tumor: structure-activity relationshipsP Workman, P R Twentyman
Biomedicine / [Publiee Pour L'A.A.I.C.I.G.]|October 1, 1978
Drug latentiation in cancer chemotherapyP Workman, J A Double
Anti-Cancer Drug Design|October 2, 1998
Bioreductive drugs into the next millenniumI J Stratford, P Workman
Radiation Research|April 1, 1980
Partition coefficient as a guide to the development of radiosensitizers which are less toxic than misonidazoleJ M Brown, P Workman
Cancer Treatment Reports|February 1, 1980
Phenytoin sodium-induced alterations in the pharmacokinetics of misonidazole in the dogR A White, P Workman
Biochemical Pharmacology|October 1, 1982
Effects of the xanthine oxidase inhibitor allopurinol on the renal clearance of nitroimidazolesP Workman, R A White
Cancer Chemotherapy and Pharmacology|January 1, 1988
When can the infusion period be safely ignored in the estimation of pharmacokinetic parameters of drugs in humans?L S Freedman, P Workman
The Journal of Pharmacology and Experimental Therapeutics|May 1, 1993
Pharmacokinetics and bioreductive metabolism of the novel benzotriazine di-N-oxide hypoxic cell cytotoxin tirapazamine (WIN 59075; SR 4233; NSC 130181) in miceM I Walton, P Workman
Biochemical Pharmacology|April 15, 1992
DT-diaphorase and cancer chemotherapyR J Riley, P Workman
Pageof 27